Ask Our Experts

FDA Approves New Alzheimer’s Treatment: What to know About Leqembi® (lecanemab)

FDA Approves New Alzheimer’s Treatment: What to know About Leqembi® (lecanemab)

Leqembi® (lecanemab) was approved to treat Alzheimer’s disease in January, 2023 under the FDA’s Accelerated Approval process for diseases with an unmet need for treatment.1 The manufacturers, Eisai pharmaceuticals, plan to submit data for full FDA approval by the end of March 2023.

Here, we answer some common questions about Leqembi and summarize what is known about its safety and effectiveness. Patients and their families should speak with their physician and weigh the potential benefits and risks before deciding whether to seek treatment with Leqembi.
Read More

post

PHM has your back

PHM has your back

The ability to live a normal life versus one that is defined by pain can change in an instant. Amanda was enjoying a weekend with friends in California’s wine country. As she took in a spectacular view, she suddenly began to experience unimaginable pain that began in her lower back and radiated down her legs.

Amanda couldn’t turn, she couldn’t walk, she couldn’t even move.

Amanda spent the next few days making agonizing trips to emergency rooms where she was given the same prescription for pain medication and told that her pain wasn’t severe enough for her to be admitted or receive an MRI.

Read More

Subscribe to our Newsletter


A doctor takes a patient's blood pressure.

Contact

Want to speak with a
representative?

Connect

Follow us
on LinkedIn